Codexis Inc
NASDAQ:CDXS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Darshan Orna Ltd
BSE:539884
|
IN |
Codexis Inc
Other
Codexis Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Codexis Inc
NASDAQ:CDXS
|
Other
-$839k
|
CAGR 3-Years
18%
|
CAGR 5-Years
34%
|
CAGR 10-Years
7%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other
$90m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Danaher Corp
NYSE:DHR
|
Other
-$125m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-44%
|
|
|
Waters Corp
NYSE:WAT
|
Other
-$23.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-17%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other
-$34m
|
CAGR 3-Years
34%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other
-$86m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Codexis Inc
Glance View
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).
See Also
What is Codexis Inc's Other?
Other
-839k
USD
Based on the financial report for Dec 31, 2025, Codexis Inc's Other amounts to -839k USD.
What is Codexis Inc's Other growth rate?
Other CAGR 10Y
7%
Over the last year, the Other growth was 64%. The average annual Other growth rates for Codexis Inc have been 18% over the past three years , 34% over the past five years , and 7% over the past ten years .
